Across TCGA pan-cancer cohorts, PRCD Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PRCD data layer compared with 23 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PRCD Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRCD expression acts as an unfavorable survival marker.

OV are the cancer types where PRCD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.132	0.541	.001	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: PRCD tumor-vs-normal RNA expression · all PRCD data types